JP2024517087A - 小児重症筋無力症を治療するための組成物及び方法 - Google Patents

小児重症筋無力症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2024517087A
JP2024517087A JP2023562610A JP2023562610A JP2024517087A JP 2024517087 A JP2024517087 A JP 2024517087A JP 2023562610 A JP2023562610 A JP 2023562610A JP 2023562610 A JP2023562610 A JP 2023562610A JP 2024517087 A JP2024517087 A JP 2024517087A
Authority
JP
Japan
Prior art keywords
myasthenia gravis
seq
pediatric
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517087A5 (https=
Inventor
ブラック，シャウン
ラムチャンドレン，シンドゥ
チュー，ヤオウェイ
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2024517087A publication Critical patent/JP2024517087A/ja
Publication of JP2024517087A5 publication Critical patent/JP2024517087A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023562610A 2021-04-12 2022-04-12 小児重症筋無力症を治療するための組成物及び方法 Pending JP2024517087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US63/219,155 2021-07-07
US202263266880P 2022-01-18 2022-01-18
US63/266,880 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024517087A true JP2024517087A (ja) 2024-04-19
JP2024517087A5 JP2024517087A5 (https=) 2025-04-22

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562610A Pending JP2024517087A (ja) 2021-04-12 2022-04-12 小児重症筋無力症を治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US20240182598A1 (https=)
EP (1) EP4323002A4 (https=)
JP (1) JP2024517087A (https=)
KR (1) KR20230169207A (https=)
AU (1) AU2022256389A1 (https=)
BR (1) BR112023021046A2 (https=)
CA (1) CA3216642A1 (https=)
CL (1) CL2023003033A1 (https=)
IL (1) IL307445A (https=)
JO (1) JOP20230247A1 (https=)
MX (1) MX2023012032A (https=)
PH (1) PH12023552841A1 (https=)
WO (1) WO2022221239A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506786A (ja) * 2017-12-13 2021-02-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506786A (ja) * 2017-12-13 2021-02-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 105, JPN6026006812, 2019, pages 4 - 1031, ISSN: 0005802368 *

Also Published As

Publication number Publication date
JOP20230247A1 (ar) 2023-10-12
MX2023012032A (es) 2023-12-08
EP4323002A4 (en) 2025-04-16
WO2022221239A1 (en) 2022-10-20
KR20230169207A (ko) 2023-12-15
BR112023021046A2 (pt) 2023-12-19
AU2022256389A1 (en) 2023-11-30
IL307445A (en) 2023-12-01
CL2023003033A1 (es) 2024-03-08
PH12023552841A1 (en) 2024-05-20
AU2022256389A9 (en) 2023-12-07
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21
US20240182598A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US20220144946A1 (en) Fcrn antibodies and methods of use thereof
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
MXPA06014299A (es) Anticuerpos contra interleucina-13 humana y uso de los mismos.
US20230265175A1 (en) High affinity antibodies targeting tau phosphorylated at serine 413
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
JP2021508366A (ja) 気分障害の治療及び診断のための抗−配列類似性１９を持つファミリー、メンバーａ５抗体の用途
KR20260050360A (ko) 만성 갑상선 안질환의 치료 방법
US20220041694A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
CA3130300A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
US20240182598A1 (en) Compositions and methods for treating pediatric myasthenia gravis
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
US20250382355A1 (en) Polypeptides effective against multiple coronaviruses
EA052034B1 (ru) Композиции и способы лечения детской миастении гравис
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
US11981745B2 (en) Anti-mesothelin antigen-binding molecules and uses thereof
CN121620371A (zh) T细胞衔接蛋白在治疗癌症中的用途
EA052645B1 (ru) Композиция для лечения и предупреждения covid-19
CN121127494A (zh) 用于治疗自身免疫性疾病的抗cd38抗体
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
EA051865B1 (ru) Антитела к fcrn и способы их применения
EA052946B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
HK1107771A (en) Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227